Seres Therapeutics (MCRB) Posts Q2 Loss of $1.45/Share

Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($1.45), $1.15 worse than the analyst estimate of ($0.30).

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Adobe Systems (ADBE) Tops Q3 EPS by 6c, Offers Guidance
• Zumiez, Inc. (ZUMZ) Misses Q2 EPS by 6c, Misses on Revenue; Offers Q3 Guidance